Gut Reactions #9 – New treatment for active ulcerative colitis (UC)

December 16, 2016 0
Tofacitinib is a new JAK inhibitor taken by mouth 10mg twice daily. Recent trials (OCTAVE) have shown significant benefit in patients with moderately active UC. The patients had previous failure or intolerance to conventional treatments. Patients receiving tofacitinib were significantly more likely to have a clinical response, healing of the colon or achieve remission than those given placebo tablets at weeks 2, 4 and 8. While this drug has been around some time, this is the latest and largest trial that has produced promising results. It is hoped that it will be licensed and made available for appropriate or selected patients towards the end of 2017.


Leave a Reply

Your email address will not be published. Required fields are marked *



At West Kent Gastroenterology, we work hard to provide our patients with top-class care. You will enjoy friendly, fast and modern treatment by a highly experienced gastroenterologist. We carefully review patient satisfaction and feedback, and at West Kent Gastroenterology we are continuously making improvements to our services, ensuring the highest level of care possible.

Clinic Locations

Nuffield Hospital
Kingswood Road, Tunbridge Wells, Kent, TN2 4UL

Sevenoaks Medical Centre
London Road, Sevenoaks, Kent, TN13 2JD

LycaHealth Canary Wharf
1 Westferry Circus, London, E14 4HD

OneWelbeck Digestive Health
1 Welbeck Street, London, W1G 0AR

Twitter

@dradamharris - 4 months

RT : If you are regularly getting heartburn please speak to a GP. In we want to spread t…

@dradamharris - 8 months

In addition to my existing clinics across London and Kent, delighted to be starting a new weekly clinic at…

© 2022 West Kent Gastroenterology Ltd.

Designed and Developed By